Ovarian cancer - topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent disease only (Review of TA 91 & TA 222) [ID468]

Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced ovarian cancer (for recurrent disease only) (Review of TA 91 & TA 222)

Status: In development
Expected date of issue: TBC
Process: MTA
Topic area:
  • Cancer
  • Gynaecology, pregnancy and birth
 

NICE project team

Executive Lead: TBC
Technical Lead: Helen Tucker
Communications manager: Laura Gibson
Project manager:

Bijal Joshi

Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: 13 March 2013
1st appraisal committee meeting: 04 September 2013
2nd appraisal committee meeting: 06 November 2013
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
07 January 2015 Please note that the appeal period for this appraisal will close at 5pm 20 January 2015
09 December 2013

The release of the FAD has been delayed.

We will provide you with an update as soon as we have further information.

12 February 2013

Trabectedin in combination with pegylated liposomal doxorubicin hydrochloride was omitted from the list of relevant interventions for people who are allergic to platinum-based compounds. This omission has been corrected in final scope.

 

Top


 

Key documents

This page was last updated: 24 April 2015